Malignant Pleural Disease Treated With Autologous T Cells Genetically Engineered to Target the Cancer-Cell Surface Antigen Mesothelin
A Phase I Clinical Trial of Malignant Pleural Disease Treated With Autologous T Cells Genetically Engineered to Target the Cancer-Cell Surface Antigen Mesothelin
Doctors at Memorial Sloan Kettering in New York and New Jersey are recruiting patients with certain cancers to participate in a clinical trial of gene-modified autologous (from the patient back to themself) T-cell transplant. The therapy removes T-cells from the body and genetically modifies them in the lab to target the mesothelioma cancer cells, multiplies them, and then re-infuses them to the patient either alone or after a round of chemotherapy. The therapy will require up to a year-long follow-up.
These cancers are eligible for the investigatory treatment:
- Malignant Pleural Disease
- Lung Cancer
- Breast Cancer
- Be age 18 years or older
- Have a diagnosis of one of the eligible cancers
- Not have central nervous system metastasis
THE STUDY INVOLVES:
- Prescreening tests to confirm eligibility of the patient to participate.
- Have blood drawn, immune cells separated and blood cells returned (leukapheresis)
- After lab modification time (3 to 6 weeks), the patient will admit to the hospital and receive chemotherapy, if assigned to that group of the study.
- The gene-edited immune cells will be infused and drugs to help promote their growth injected.
- Recovery in the hospital for several weeks.
- Follow up over the course of the following year.
LOCATIONS & CONTACTS:
The study will take place at Memorial Sloan Kettering Cancer Center. Map.
Prasad Adusumilli, MD | 212-639-8093
Marjorie Zauderer, MD | 646-888-4656
Memorial Sloan Kettering Cancer Center
Or go online: